Novartis Pharmaceuticals added a Yardley site to NCT07517263, the open-label long-term extension study for pelacarsen (TQJ230), which targets lipoprotein(a)-driven cardiovascular disease
The dried bacterial pellet was solubilized in 20 ml of B-PER (78243, Thermo Fisher Scientific), supplemented with protease inhibitors (1 g ml 1 of leupeptin, 1 g ml 1 of AEBSF HCl and 1 l of benzonase) and 5 mM imidazole and then transferred to a 50-ml centrifuge tube
It contains 0.9% benzyl alcohol as a preservative to inhibit the growth of bacteria, ensuring the solution remains sterile for multiple uses
Methods Enzymol 1999
Seek urgent medical attention if you develop sudden or severe neurological symptoms, such as significant weakness, loss of coordination, visual disturbances, or confusion, as these may indicate more serious neurological complications requiring immediate assessment